title: Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1.
abstract: OBJECTIVE
  To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms.
  
  
  METHODS
  TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells.
  
  
  RESULTS
  The survival inhibition rate of combined application of 100 μg/ml TRAIL and 1 μg/ml oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis.
  
  
  CONCLUSIONS
  A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.
authors.affiliation: Department of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. huangtao@mail.cmu.edu.cn
authors.forename: Tao
authors.initials: T
authors.lastname: Huang
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Gong
authors.forename: Xiu-Cheng
authors.initials: XC
authors.lastname: Li
authors.forename: Chun-Ping
authors.initials: CP
authors.lastname: Zou
authors.forename: Guang-Jian
authors.initials: GJ
authors.lastname: Jiang
authors.forename: Xu-Hui
authors.initials: XH
authors.lastname: Li
authors.forename: Hao
authors.initials: H
authors.lastname: Qian
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D000077150:Oxaliplatin; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D015996:Survival Rate; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009944:Organoplatinum Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; D000077150:Oxaliplatin